Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib dose-escalation and expansion study in advanced EGFR- or HER2-mutant NSCLC
NL-OMON53437Phase 1Not yet recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by ArriVent BioPharma. Primary endpoints: Incidence and severity of adverse events including dose-limiting toxicities, Confirmed objective response rate and 1 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON53437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53437.